del Pozo, V, Bobolea, I, Rial, MJ, Espigol-Frigolé, G, Laqué, RS, Hernández-Rivas, JM, Mora, E, Crespo-Lessmann, A, Alonso, JLI, Sosa, MSD, Maza-Solano, J, Atienza-Mateo, B, Bañas-Conejero, D, Moure, AL, Rúa-Figueroa, I. Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases. Frontiers in Immunology. 2024; 14DOI:10.3389/fimmu.2023.1310211. PMID:38250075. IF:5.900(Q1/2D).

Quesada-López, T, Cereijo, R, Blasco-Roset, A, Mestres-Arenas, A, Prieto, P, Domingo, JC, Villarroya, F, Domingo, P, Giralt, M. Divergent effects of the antiretroviral drugs, dolutegravir, tenofovir alafenamide, and tenofovir disoproxil fumarate, on human adipocyte function. BIOCHEMICAL PHARMACOLOGY. 2024; 220DOI:10.1016/j.bcp.2023.116010. PMID:38154544. IF:5.600(Q1/1D).

Provencio, M, de Lope, LR, Serna-Blasco, R, Nadal, E, Tain, PD, Massuti, B, González-Larriba, JL, Insa, A, Sánchez-Hernández, A, Casal-Rubio, J, Garcia-Campelo, R, López, SS, Rogado, J, Martínez-Martí, A, Bosch-Barrera, J, Bernabé, R, Estévez, SV, Ponce, S, de Castro, J, Sarto, JC, Reguart, N, Dómine, M, Aguilar, A, Majem, M, Estival, A, Cabia, SP, Martín, AL, González, MAS, Cobo, M, Camps, C, Barneto, I, Calvo, V, Collazo-Lorduy, A, Cruz-Bermúdez, A, Romero, A. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC. LUNG CANCER. 2024; 194DOI:10.1016/j.lungcan.2024.107865. PMID:38945004. IF:4.400(Q1/2D).

Giménez, S, Vaqué-Alcázar, L, Zhu, NL, Benejam, B, Arranz, J, Maure-Blesa, L, Videla, L, Carmona-Iragui, M, Barroeta, I, Rebillat, AS, Rodriguez-Baz, I, Bejanin, A, Arriola-Infante, JE, Bueno, A, Fernandez, S, Ribas, L, Zsadanyi, SE, Morcillo-Nieto, AO, Alcolea, D, Lisgaras, CP, Blessing, E, Osorio, RS, Lleo, A, Fortea, J. Impact of Alzheimer's disease on sleep in adults with Down syndrome. ALZHEIMERS & DEMENTIA. 2025; 21(7)DOI:10.1002/alz.70400. PMID:40604343. IF:11.100(Q1/1D).

Buchmeier, EL, Reck, M, Girard, N, Nadal, E, Gay, CM, Filippi, AR, Martin, LW, Petersen, C, Cairns, DA, Roch, B, Attili, I, Alvarez, RA, Boyer, A, Tarruella, MM, Robinson, A, Levra, MG, Li, L, Perez, ID, Georgoulia, N, Spicer, J. Neoadjuvant (neoadj) durvalumab (D) plus chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB-IIIB NSCLC: interim analysis (IA) of the phase 2 MDT-BRIDGE study. Oncology Research and Treatment. 2026; 49DOI:. PMID:. IF:1.600(Q4/9D).

Giani, C, Baldi, GG, Ljevar, S, Denu, RA, Andelkovic, V, Han, I, Brunello, A, Napolitano, A, Bhadri, VA, Scanferla, R, Garcia, AS, Abreu, MH, Campos, F, Ogura, K, Wong, DD, Bae, S, Marquina, G, Mazzocca, A, Yang, V, Nakazawa, MS, Kim, HS, Chiusole, B, Thway, K, Antonescu, C, Bellan, E, Bovée, JVMG, Davis, JL, Tos, APD, Di Blasi, E, Lazar, AJ, Sbaraglia, M, Schaefer, IM, Taverna, S, Chen, TWW, Miceli, R, Gronchi, A, Stacchiotti, S. International multicenter retrospective study on pleomorphic rhabdomyosarcoma (P-RMS), a PUSH platform study: outcome of primary localized disease. ESMO Open. 2026; 11(2)DOI:10.1016/j.esmoop.2025.106044. PMID:41564817. IF:8.300(Q1/2D).

Christoph, D, Paz-Ares, L, Borghaei, H, Liu, S, Peters, S, Herbst, R, Stencel, K, Tarruella, MM, Czyzewicz, G, Caro, RB, Lee, KH, Johnson, ML, Karadurmus, N, Grohé, C, Cuchelkar, V, Graupner, V, Kaul, M, Lin, YC, Chakrabarti, D, Bhatt, K, Reck, M. IMforte: Results from a Phase 3 study of first-line (1L) maintenance treatment (tx) with lurbinectedin (lurbi) plus atezolizumab (atezo) vs atezo in patients (pts) with ES-SCLC. Oncology Research and Treatment. 2026; 49DOI:. PMID:. IF:1.600(Q4/9D).

López-Tarruella, S, Guerrero-Zotano, A, Antolín, S, Cruz, J, Martínez, P, Rodríguez, CA, Falo, C, Rodríguez-Lescure, A, Adrover, E, Hernández, M, Andrés, R, Chacón, JI, Romero, JLA, Miguel, A, Gómez-Raposo, C, Margelí, M, González, I, Guerra, JA, Antón, A, Tibau, A, Miralles, JJ, Escudero, MJ, Bezares, S, Rojo, F, Alvarez, I. Clinical subtypes in breast cancer patients with brain metastases from an ambispective registry of advanced breast cancer, GEICAM/2014-03 (RegistEM). Therapeutic Advances in Medical Oncology. 2026; 18DOI:10.1177/17588359261421813. PMID:41732657. IF:4.200(Q2/3D).